Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Preclinical News

Salk study unveils LIF's mechanism in form of pancreatic cancer

Lauren Martz, Associate Editor
April 17, 2019 9:58 PM UTC

A new study from Salk Institute for Biological Studies pinpoints new mechanistic details about how LIF promotes pancreatic cancer, providing preclinical support for Northern Biologics' lead candidate.

In a Nature paper published Wednesday, Salk's Tony Hunter and colleagues showed that LIF is secreted by pancreatic stellate cells (PSCs) to drive pancreatic ductal adenocarcinoma (PDAC) progression and chemoresistance...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Celgene Corp.

Northern Biologics Inc.

Salk Institute for Biological Studies